3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades

Impact · against what's priced in

The article provides no catalyst for Medtronic or Abbott, as the reported revenue beats and guidance raises are already reflected in their current valuations. Becton Dickinson shows positive momentum with a significant surge in free cash flow and debt reduction, though its long-term impact depends on whether this translates into the expanded buybacks the market hasn't yet priced in.

ABT+0.00

Already priced in

The price assumes

the safety of a diversified healthcare conglomerate